Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Generation of Antibiotics Disrupts Quorum Sensing

By LabMedica International staff writers
Posted on 24 Mar 2009
Drug developers are working on a new generation of antibiotics that do not kill bacteria but instead disrupt the communication system known as "quorum sensing,” which induces the microorganisms to manufacture disease-causing toxins.

Several types of bacteria, including such human pathogens as Vibrio cholerae and Escherichia coli O157:H7, can grow within a host without harming it, until they reach a certain concentration. More...
They become aggressive when their numbers become sufficient to overcome the host's immune system and form a biofilm, leading to disease. The language of quorum sensing is based on the bacterial population producing and detecting signaling molecules known as autoinducers.

Investigators from the Albert Einstein College of Medicine (New York, NY, USA) focused on the bacterial enzyme 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase (MTAN), which is involved in S-adenosylmethionine–related quorum sensing pathways that induce bacterial pathogenesis factors. To block MTAN activity they created a series of transition state analogs, MT-DADMe-Immucillin-A, EtT-DADMe-Immucillin-A, and BuT-DADMe-Immucillin-A, which are slow-onset, tight-binding inhibitors of V. cholerae MTAN (VcMTAN).

Results published in the March 8, 2009, online edition of the journal Nature Chemical Biology revealed that in V. cholerae cells, the compounds were potent MTAN inhibitors. Structural analysis of VcMTAN with BuT-DADMe-Immucillin-A revealed interactions contributing to the high affinity. The compounds disrupted autoinducer production in a dose-dependent manner without affecting growth. MT- and BuT-DADMe-Immucillin-A also inhibited autoinducer-2 production in enterohemorrhagic E. coli O157:H7.

By targeting quorum sensing rather than bacterial growth, the new drugs avoided stimulating the bacteria into becoming resistant. The investigators tested the compounds on 26 successive generations of both bacterial species, and found that the 26th generations were as sensitive to the antibiotics as the first. "In our lab, we call these agents everlasting antibiotics,” said senior author Dr. Vern Schramm, professor of biochemistry at Albert Einstein College of Medicine.

Related Links:

Albert Einstein College of Medicine



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.